EFFICACY AND SAFETY IN THE USE OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS AT HIGH RISK OF FRACTURE IN AN OUTPATIENT CASE SERIES FROM THE MARCHE REGION

被引：0
|
作者：
Farina, A. [1 ]
Pingiotti, E. [1 ]
Martino, G. P. [1 ]
Bitti, G. [1 ]
Angelici, S. [1 ]
机构：
[1] Osped Civile A Murri, Internal Med, Fermo, Italy
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2024年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P147
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [31] Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Api, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (08) : 1480 - 1481
  • [32] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
    Saag, Kenneth
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul D.
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] Underuse of osteoporosis treatment in postmenopausal women at high risk for low trauma fracture: Evidence from national osteoporosis risk assessment (NORA).
    Siris, ES
    Weiss, TW
    Barlas, S
    Chen, Y
    Barrett-Connor, E
    Miller, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S380 - S380
  • [34] Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
    Brown, Jacques P.
    Engelke, Klaus
    Keaveny, Tony M.
    Chines, Arkadi
    Chapurlat, Roland
    Foldes, A. Joseph
    Nogues, Xavier
    Civitelli, Roberto
    De Villiers, Tobias
    Massari, Fabio
    Zerbini, Cristiano A. F.
    Wang, Zhenxun
    Oates, Mary K.
    Recknor, Christopher
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (11) : 2139 - 2152
  • [35] OSTEOPOROSIS TREATMENT RANKING IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF FRACTURE IN BRAZIL: MCDA APPROACH
    Mensor, L.
    Rosim, M. P.
    Marchesan, T.
    Amaral, L. Murta
    VALUE IN HEALTH, 2023, 26 (06) : S148 - S148
  • [36] Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk? Reply
    Bone, HG
    Santora, AC
    Chattopadhyay, A
    Liberman, U
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (11) : 2064 - 2065
  • [37] Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety
    Gatti-Mays, Margaret E.
    Venzon, David
    Galbo, Claudia E.
    Singer, Andrea
    Reynolds, James
    Makariou, Erini
    Kallakury, Bhaskar
    Heckman-Stoddard, Brandy M.
    Korde, Larissa
    Isaacs, Claudine
    Warren, Robert
    Gallagher, Ann
    Eng-Wong, Jennifer
    CANCER PREVENTION RESEARCH, 2016, 9 (03) : 225 - 233
  • [38] Expected Fracture Outcomes and Associated Costs of Romosozumab Preceding or Following Alendronate in Postmenopausal Women at Very High Fracture Risk in the United States
    Yeh, Eric Junyen
    Raad, Angie
    McDermott, Michele
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 52 - 53
  • [39] Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study
    Pluskiewicz, W.
    Drozdzowska, B.
    Adamczyk, P.
    CLIMACTERIC, 2013, 16 (01) : 117 - 126
  • [40] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 ARCH Study (Active-contRolled fraCture study in postmenopausal women with osteoporosis at High risk).
    Saag, Kenneth G.
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S54 - S55
12345